Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salbutamol for COPD patients with lung cancer undergoing VATS
ChiCTR2500109842Phase 4Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of salbutamol in chronic obstructive pulmonary disease (COPD), bronchial carcinoma and postoperative respiratory complications (PRC) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Lung collapse at 5 minutes. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
salbutamol
03
Conditions
chronic obstructive pulmonary disease (COPD)bronchial carcinomapostoperative respiratory complications (PRC)
Beyond the preview
Go deeper on ChiCTR2500109842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109842.